Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion Inc (ACON) delivers innovative diagnostic solutions for chronic low back pain through its Nociscan SaaS platform, combining MRS technology with AI-driven biomarker analysis. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical advancements, financial milestones, and strategic initiatives.
Access timely press releases covering FDA communications, peer-reviewed study results, and partnership announcements with leading medical institutions. Our curated collection includes earnings reports, technology updates, and market expansion developments critical for evaluating ACON's position in medical imaging innovation.
Bookmark this page for streamlined access to verified information about Nociscan's clinical adoption, intellectual property developments, and evidence-based research outcomes. Stay informed about ACON's progress in transforming spine diagnostics through objective, noninvasive solutions supported by proprietary signal processing algorithms.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025. The presentation is scheduled for April 23, 2025, at 12:30 PM ET, where CEO Brent Ness will discuss the company and its recent value-driving initiatives. In conjunction with the event, the company has released an updated investor presentation available on their investor relations website.
Aclarion (NASDAQ: ACON) announced the publication of a peer-reviewed cost-effectiveness analysis of their Nociscan technology in Clinicoeconomics and Outcomes Research. The study demonstrates that Nociscan, a SaaS platform that helps identify chronic low back pain locations, is more cost-effective than traditional provocative discography.
The analysis reveals that Nociscan saves $1,712 per patient and improves surgical success rates by 10%. The technology uses biomarkers and AI algorithms to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine, addressing a global healthcare challenge affecting approximately 266 million people worldwide with degenerative spine disease and low back pain.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025.
CEO Brent Ness will deliver a presentation on Wednesday, April 23, 2025, at 12:30 PM ET and will be available for questions afterward. The company will also conduct in-person 1x1 investor meetings on Thursday, April 24, 2025, at the Paris Hotel & Casino in Las Vegas.
Aclarion (NASDAQ: ACON) has announced the expansion of its Nociscan product availability to the Medical Imaging Center of Southern California's (MICSC) Santa Monica location, extending beyond their existing Beverly Hills facility. Nociscan, a SaaS platform that helps physicians identify chronic low back pain locations through biomarkers and AI algorithms, was previously only available at MICSC's Beverly Hills center.
Dr. Bradley Jabour, MICSC's founder, was featured in a November 2024 article about Nociscan in MAGNETOM Flash, a Siemens Healthineers publication. The expansion into Santa Monica strengthens Aclarion's presence in Los Angeles, a strategic market with over 3.8M residents and the second-most populous city in the United States.
Nociscan is the first evidence-supported platform to noninvasively help physicians differentiate between painful and nonpainful lumbar spine discs by quantifying chemical biomarkers associated with disc pain.
Aclarion (NASDAQ: ACON) has strengthened its position following Q1 2025 strategic initiatives. The company raised over $20 million in Q1, maintaining nearly $15 million in cash with zero debt and no preferred equity. The company is now fully Nasdaq compliant, meeting both bid price and shareholder equity requirements.
The company's CLARITY trial for Nociscan, their AI-powered solution for identifying chronic low back pain locations, is fully funded with interim results expected in Q2 2026. Aclarion has secured additional payer approvals in England and expanded physician referral and commercial support in the U.S.
Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine, demonstrating a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced the submission of an 8-K filing for stakeholder review. The company plans to file its 10-K by the end of March 2025, accompanied by a comprehensive corporate update.
Aclarion (NASDAQ: ACON) has announced expansion plans for its Nociscan technology across multiple sites in New York and New Jersey through RadNet affiliates. Lenox Hill Radiology (LHR), operating 79 locations in New York, and New Jersey Imaging Network (NJIN), with 33 locations, will increase Nociscan accessibility in response to growing market demand.
The expansion builds on existing Nociscan sites and is facilitated by increased MR Spectroscopy (MRS) availability and enhanced remote operations capabilities within RadNet. LHR Park Avenue serves leading spine physicians from private practices and organizations like Weill Cornell, while NJIN-Union supports both local and out-of-market referrals through convenient airport access.
Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively identify painful discs in the lumbar spine, demonstrating a 97% surgical success rate when all pain-positive discs identified by Nociscan are treated.
Aclarion (Nasdaq: ACON) has secured its first commercial agreement with Scripps Health in San Diego, expanding access to its Nociscan technology. The agreement brings the diagnostic solution to Southern California's largest healthcare system, serving over 3.2M people in the San Diego Metro area.
Nociscan, which uses MR Spectroscopy and AI to identify chronic low back pain sources, will be available at Scripps Green Hospital. Dr. Robert Eastlack, Orthopedic Surgeon at Scripps Health, emphasized the technology's value in providing additional diagnostic information for patients previously referred to Beverly Hills for the procedure.
Scripps Health operates five hospitals and 19 outpatient facilities, treating 500,000 patients annually through 2,600 affiliated physicians. The system will implement Nociscan both in clinical practice and research trials, supporting their mission to advance spine care.
Aclarion (NASDAQ: ACON), a healthcare technology company specializing in MRS and AI for back and neck pain treatment optimization, has announced the adjournment of its Special Meeting of Stockholders originally scheduled for February 28, 2025.
The meeting has been rescheduled to March 5, 2025, at 9:30 a.m. Mountain Time at the company's Broomfield, Colorado office. The adjournment aims to solicit additional votes for proposals outlined in the company's proxy statement filed with the SEC on February 3, 2025.
The record date remains January 6, 2025. Previously submitted proxies will remain valid unless revoked. Shareholders can modify their votes until 11:59 p.m. Mountain Time on March 4, 2025, either through Internet voting or by submitting a new signed proxy.
Aclarion (Nasdaq: ACON) announced its participation in the 2025 Spine Summit, where Dr. Nicholas Theodore will showcase the company's NOCISCAN technology. NOCISCAN is a pioneering SaaS platform that combines MR Spectroscopy with augmented intelligence to help physicians identify the location of chronic low back pain.
Dr. Theodore, who serves as Professor at Johns Hopkins University School of Medicine and holds multiple director positions, will present 'NOCISCAN, Augmented Intelligence, and Low Back Pain Decision Support' on February 21, 2025. The technology is particularly significant given that approximately 266 million people worldwide suffer from degenerative spine disease and low back pain.
NOCISCAN is the first evidence-supported platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine by objectively quantifying chemical biomarkers associated with disc pain.